Healthcare systems

A multifaceted, clinic-level intervention results in a marked increase in the proportion of people with type 2 diabetes and atherosclerotic cardiovascular disease receiving appropriate medications, shows the COORDINATE randomized trial.

A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.

Formal recognition of type 2 diabetes remission in primary care may lead to suboptimal health monitoring, a study suggests.

Findings from a nationally representative US survey show that a substantial minority of people with diabetes ration their use of insulin because of issues with affordability.

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

Researchers find that a single questionnaire item assessing vitality predicts major adverse cardiovascular events in people with type 2 diabetes.

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

Findings from the phase 2 ARCADIA trial suggest that treatment with a glucokinase activator may aid the recovery of people with diabetes who are hospitalized with severe COVID-19.

Clinical complexity and treatment burden have both increased over recent years among people with diabetes in the USA, say researchers.

The proven cardiovascular benefits of SGLT2 inhibitors has not led doctors to prioritize their use in people at high risk, show findings from UK general practice.

Increased team-based continuity of care correlates with decreased risk for cardiovascular disease in people with type 2 diabetes, researchers report in Diabetes Care.

Physicians feel that nonalcoholic fatty liver disease is sidelined in type 2 diabetes management and should be formally incorporated into routine primary care pathways, say Australian researchers.

UK researchers find people with type 2 diabetes are increasingly being cared for in specialist settings, rather than by family doctors.

Young people with type 1 diabetes are at increased risk for hospitalization for acute complications at the time of transition from pediatric to adult care, say researchers.

Intensification of diabetes medications in older adults at the point of discharge from hospital is associated with an increased risk for hypoglycemia, without gains in glycemic control, research suggests.

Researchers have found evidence that almost one in 20 people diagnosed with type 2 diabetes in routine clinical care later achieve remission.

Reducing the cost of SGLT2 inhibitors by around 17% would make them cost-effective for use in people with type 2 diabetes in low- and middle-income countries, study findings indicate.

A large systematic review and meta-analysis has identified racial/ethnic differences in the risk for complications and all-cause mortality among people with diabetes.

Nephrologist Ian de Boer joins primary care physician Amrit Lamba to discuss how the recent approval of finerenone and extension of the dapagliflozin label is likely to influence the treatment of kidney disease in people with type 2 diabetes.

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.